Business Context and Reporting Period
This Form 6-K filing by Adlai Nortye Ltd. covers the month of July 2026, specifically dated July 16, 2026. The company is a foreign private issuer based in the Cayman Islands. The filing serves to disseminate a press release regarding a clinical trial milestone for its lead candidate, AN9025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
There are no financial material changes reported in this filing. The significant operational update is the dosing of the first patient in the intermittent weekly dosing arm of the global Phase 1 trial for the Pan-RAS(ON) inhibitor AN9025.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical trial progress. The filing does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the context of the clinical trial update.
Investor Verification Checklist
- Verify the full text of the attached press release (Exhibit 99.1) for detailed trial design and safety data.
- Confirm the status of other dosing arms in the AN9025 Phase 1 trial.
- Review recent financial filings (e.g., Form 20-F) for cash runway and burn rate, as this 6-K contains no financial data.
- Monitor for subsequent safety or efficacy data readouts from the Phase 1 trial.